Биостатистика, фармакокинетика и клинические исследования.

Домашняя страница
- О сайте
Материалы
- Быстрые команды R Project
- Ссылки
Инструменты
- Рандомизационный список
Блог
Контакты
Профиль
- Войти
- Зарегистрироваться

Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0

Галерея

Information by Drug Class
Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-03 By FDA
Registered Outsourcing Facilities
Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-03 By FDA
AFLURIA , AFLURIA SOUTHERN HEMISPHERE
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-07-03 By FDA
Exela Pharma Sciences, LLC - 709859 - 07/02/2025
Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-03 By FDA
Human medicines European public assessment report (EPAR): Pregabalin Viatris Pharma (previously Pregabalin Pfizer), pregabalin, Date of authorisation: 10/04/2014, Revision: 36, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-03
Condition-Specific Meeting Reports and Other Information Related to Patients' Experience
Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-03 By FDA
Upcoming EL-PFDD Meetings
Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-03 By FDA
FDA Listing of Authorized Generics
Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-03 By FDA
Human medicines European public assessment report (EPAR): Lyvdelzi (previously Seladelpar Gilead), seladelpar lysine dihydrate, Revision: 3, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-03
Human medicines European public assessment report (EPAR): Ziihera, zanidatamab, Date of authorisation: 27/06/2025, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-03
Human medicines European public assessment report (EPAR): Tivdak, tisotumab vedotin, Date of authorisation: 28/03/2025, Revision: 1, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-03
FDA grants accelerated approval to sunvozertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations
Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-02 By FDA
Novel Drug Approvals for 2022
Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-02 By FDA
Novel Drug Approvals for 2024
Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-02 By FDA
Novel Drug Approvals for 2023
Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-02 By FDA

Предыдущие записи

Тема: Scaffold от Danny Cooper.